Investors

  1. Investor Relations

Investors

Investor Relations

Corporate Profile

CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients.


With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis.


We are active in research and are constantly developing new and innovative products for human genetics. We are focused on helping to end the diagnostic odyssey of our patients by offering the broadest genetic diagnostic portfolio, and on using our global knowledge of rare hereditary diseases to provide solutions for our pharmaceutical partners that accelerate the development of orphan drugs.


We are committed to ‘un-rare’ rare diseases by using our worldwide knowledge in the rare disease market, understanding the epidemiology, analyzing clinical heterogeneity of the more than 3800 diseases and developing innovative biomarkers. Based on this knowledge we are bringing rationality to treatment decisions and, thereby, accelerate the development of new orphan drugs.

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
Nov 07, 2019
CAMBRIDGE, Mass. and ROSTOCK, Germany, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical
Nov 07, 2019
Cambridge, MA, USA & Rostock, Deutschland, 6. November 2019 – Centogene B.V. („CENTOGENE“ oder das „Unternehmen“), ein auf seltene Erkrankungen spezialisiertes Unternehmen, welches klinische und genetische Daten zur Beantwortung medizinischer Fragen für Patienten, Ärzte und pharmazeutische
Oct 28, 2019
CAMBRIDGE, Mass. and ROSTOCK, Germany, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Centogene B.V. (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical
Events
More events are coming soon.